Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Receivables (2016 - 2026)

Veracyte's Receivables history spans 14 years, with the latest figure at $44.7 million for Q4 2025.

  • On a quarterly basis, Receivables fell 4.01% to $44.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.7 million, a 4.01% decrease, with the full-year FY2025 number at $44.7 million, down 4.01% from a year prior.
  • Receivables hit $44.7 million in Q4 2025 for Veracyte, down from $47.8 million in the prior quarter.
  • Over the last five years, Receivables for VCYT hit a ceiling of $53.8 million in Q1 2025 and a floor of $27.9 million in Q1 2021.
  • Historically, Receivables has averaged $43.3 million across 5 years, with a median of $43.3 million in 2022.
  • Biggest five-year swings in Receivables: soared 128.65% in 2021 and later fell 8.28% in 2023.
  • Tracing VCYT's Receivables over 5 years: stood at $41.5 million in 2021, then increased by 6.17% to $44.0 million in 2022, then decreased by 8.28% to $40.4 million in 2023, then grew by 15.22% to $46.5 million in 2024, then dropped by 4.01% to $44.7 million in 2025.
  • Business Quant data shows Receivables for VCYT at $44.7 million in Q4 2025, $47.8 million in Q3 2025, and $50.8 million in Q2 2025.